FR149175, a β_3-Adrenoceptor-Selective Agonist, Is a Possible Therapeutic Agent for Non-Insulin-Dependent Diabetes Mellitus

Access this Article

Author(s)

Abstract

We examined whether FR149175 (ethyl-[(<I>S</I>)-8-[(<I>R</I>)-2-(3-chlorophenyl)-2-hydroxyethylamino]6, 7, 8, 9-tetrahydro-5<I>H</I>-benzocyclohepten-2-yloxy]acetate monohydrochloride monohydrate), a selective agonist for the β<SUB>3</SUB>-adrenoceptor, is a possible therapeutic agent for non-insulin-dependent diabetes mellitus (NIDDM). FR149175 had hypoglycemic effects with an increase in the level of plasma insulin in normal rats. In Zucker fatty rats, an animal model of NIDDM, repeated administration of the drug improved hyperinsulinemia and showed a tendency to decrease the area under the curve (AUC)for plasma glucose levels in the glucose tolerance test. Moreover, FR149175 decreased plasma triglyceride, free fatty acid and total cholesterol levels in the rats. Body weight gain in the rat was suppressed by FR149175 as well. These results suggest that FR149175 has antiobesity and antidiabetic effects and that this drug may be useful for treating NIDDM.

Journal

  • The Japanese Journal of Pharmacology

    The Japanese Journal of Pharmacology 74(1), 109-112, 1997-05-01

    The Japanese Pharmacological Society

References:  11

Cited by:  1

Codes

  • NII Article ID (NAID)
    10008678599
  • NII NACSIS-CAT ID (NCID)
    AA00691188
  • Text Lang
    ENG
  • Article Type
    Journal Article
  • ISSN
    00215198
  • NDL Article ID
    4219991
  • NDL Source Classification
    ZS51(科学技術--薬学)
  • NDL Call No.
    Z53-D199
  • Data Source
    CJP  CJPref  NDL  J-STAGE 
Page Top